Obseva (OBSV) Scheduled to Post Quarterly Earnings on Monday

Obseva (NASDAQ:OBSV) is set to announce its earnings results before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.

Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, May 9th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. On average, analysts expect Obseva to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of OBSV opened at $8.96 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.73 and a current ratio of 6.73. The company has a 50-day moving average price of $10.50. The firm has a market cap of $408.84 million, a P/E ratio of -4.69 and a beta of 0.92. Obseva has a one year low of $8.83 and a one year high of $19.40.

Several analysts have recently commented on OBSV shares. Credit Suisse Group reduced their target price on Obseva from $24.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday, July 29th. Zacks Investment Research downgraded Obseva from a “hold” rating to a “sell” rating in a research note on Wednesday. HC Wainwright set a $44.00 price target on Obseva and gave the company a “buy” rating in a research note on Wednesday, June 5th. Wedbush reiterated an “outperform” rating and set a $38.00 price target on shares of Obseva in a research note on Thursday, July 18th. Finally, ValuEngine upgraded Obseva from a “hold” rating to a “buy” rating in a research note on Thursday. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $27.50.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Read More: What is quantitative easing?

Earnings History for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.